Want to see IVVD full AI Analyst Report?
IVVD Stock Chart & Stats
$0.61
<$0.01(0.49%)
At close: 4:00 PM EDT
$0.61
<$0.01(0.49%)
Day’s Range― - ―
52-Week Range$0.52 - $3.07
Previous CloseN/A
Volume1.33M
Average Volume (3M)5.17M
Market Cap
$293.73M
Enterprise Value$127.86
Total Cash (Recent Filing)$160.08M
Total Debt (Recent Filing)$8.39M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Nov 05, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding294,758,760
10 Day Avg. Volume2,813,339
30 Day Avg. Volume5,173,640
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.76
Price to Sales (P/S)7.96
P/FCF Ratio-7.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside1539.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.53
Revenue Forecast (FY)$60.15M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginGrowing revenue and very high gross margins indicate attractive product economics as PEMGARDA sales expand. If sustained, this provides a strong foundation for operating leverage once clinical investment moderates and commercialization broadens.
Low Financial LeverageThe conservative capital structure limits interest and refinancing pressure, giving Invivyd greater flexibility to fund development and commercialization. Low debt is particularly valuable for a biotech facing uncertain regulatory timing and substantial research expenditures.
Commercial And Clinical ProgressProduct growth alongside advancement of the pivotal DECLARATION program strengthens Invivyd's commercial and pipeline prospects. Successful execution could expand the addressable market and create a broader revenue base beyond the current antibody product.
Bears Say
Persistent Losses And Cash BurnLarge losses and negative operating cash flow show that current revenue does not yet fund the business. Continued clinical spending could require additional external financing, creating dilution risk and making long-term profitability dependent on successful development.
PEMGARDA Regulatory Transition RiskThe planned end of emergency authorization introduces procedural and approval uncertainty for a key commercial product. Invivyd must secure a durable regulatory pathway to preserve access, revenue continuity, and confidence among immunocompromised patients.
Nasdaq Listing Compliance RiskFailure to regain compliance could lead to further remedial action or eventual delisting, increasing administrative and financing friction. Although not an operating issue itself, listing uncertainty can constrain institutional participation and complicate future capital access.
Invivyd News
IVVD FAQ
What was Invivyd’s price range in the past 12 months?
Invivyd lowest stock price was $0.52 and its highest was $3.07 in the past 12 months.
What is Invivyd’s market cap?
Invivyd’s market cap is $293.73M.
When is Invivyd’s upcoming earnings report date?
Invivyd’s upcoming earnings report date is Nov 05, 2026 which is in 72 days.
How were Invivyd’s earnings last quarter?
Invivyd released its earnings results on Aug 13, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.107 by -$0.033.
Is Invivyd overvalued?
According to Wall Street analysts Invivyd’s price is currently Undervalued.
Does Invivyd pay dividends?
Invivyd does not currently pay dividends.
What is Invivyd’s EPS estimate?
Invivyd’s EPS estimate is -0.13.
How many shares outstanding does Invivyd have?
Invivyd has 294,758,760 shares outstanding.
What happened to Invivyd’s price movement after its last earnings report?
Invivyd reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.107. Following the earnings report the stock price went up 5.109%.
Which hedge fund is a major shareholder of Invivyd?
Currently, no hedge funds are holding shares in IVVD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invivyd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (1539.34% Upside)
$10.00 (1539.34% Upside)
Blogger Sentiment
Neutral
IVVD Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 6.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.0%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
145.56%
Trailing 12-Months
Company Description
Invivyd
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
IVVD Company Deck
IVVD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong commercial momentum (PEMGARDA +22% YoY), advancing pivotal trial progress with encouraging safety signals (IDMC reduced monitoring), confirmed neutralization versus a recent Omicron subvariant, an expanding discovery pipeline, and a robust cash position after an April ATM raise. Near-term challenges include elevated clinical spend and burn during the pivotal, continued uncertainty around regulatory outcomes and efficacy readouts driven by event rates, declining COVID vaccine revenue, and imperfect external surveillance and media traction. On balance, concrete operational and scientific progress and expected high efficacy positioning outweigh the near-term financial and market uncertainties.View all IVVD earnings summariesIVVD Stock 12 Month Forecast
Average Price Target
$10.00
▲(1539.34% Upside)
Technical Analysis
Larimar Therapeutics
―
Rocket Pharmaceuticals
―
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
9.61% Insiders
7.58% Mutual Funds
41.59% Other Institutional Investors
33.39% Public Companies and Individual Investors